→
Boston Scientific Corp (BSX) is currently priced at $46.91, reflecting a change of +0.34% from the previous close of $46.75. The stock has a day range of $46.20 to $47.22, with a 52-week high of $109.47 and a low of $46.00, indicating significant volatility within the past year. The company's market cap is not provided.
Investors may consider the ongoing developments in product approvals and market responses as they evaluate Boston Scientific's performance.
Some investors cite Boston Scientific's potential for growth in the neurovascular market following the clearance of the Penumbra Thunderbolt technology, which may enhance their product offerings. Analysts from Truist and BTIG have reiterated buy ratings, indicating confidence in the company's future performance despite recent price declines.
The stock recently slumped to a 52-week low, raising concerns about its current valuation and market position. This downward trend has been highlighted in multiple reports, suggesting potential challenges in maintaining investor sentiment.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Boston Scientific Corp (BSX) is currently priced at $46.91, reflecting a change of +0.34% from the previous close of $46.75. The stock has a day range of $46.20 to $47.22, with a 52-week high of $109.47 and a low of $46.00, indicating significant volatility within the past year. The company's market cap is not provided.
The stock recently slumped to a 52-week low, raising concerns about its current valuation and market position. This downward trend has been highlighted in multiple reports, suggesting potential challenges in maintaining investor sentiment.
Some investors cite Boston Scientific's potential for growth in the neurovascular market following the clearance of the Penumbra Thunderbolt technology, which may enhance their product offerings. Analysts from Truist and BTIG have reiterated buy ratings, indicating confidence in the company's future performance despite recent price declines.
Some investors cite Boston Scientific's potential for growth in the neurovascular market following the clearance of the Penumbra Thunderbolt technology, which may enhance their product offerings. Analysts from Truist and BTIG have reiterated buy ratings, indicating confidence in the company's future performance despite recent price declines. The stock recently slumped to a 52-week low, raising concerns about its current valuation and market position. This downward trend has been highlighted in multiple reports, suggesting potential challenges in maintaining investor sentiment.
Boston Scientific Corp (BSX) is currently priced at $46.91, reflecting a change of +0.34% from the previous close of $46.75. The stock has a day range of $46.20 to $47.22, with a 52-week high of $109.47 and a low of $46.00, indicating significant volatility within the past year. The company's market cap is not provided.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for BSX at helmterminal.dev/analyze/BSX, updated continuously during US market hours. No signup required.